Your SlideShare is downloading. ×
SMi Group's 7th annual Advances in Cell Based Assays conference
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

SMi Group's 7th annual Advances in Cell Based Assays conference

247
views

Published on

SMi Group's 7th annual Advances in Cell Based Assays conference is back this November in London

SMi Group's 7th annual Advances in Cell Based Assays conference is back this November in London

Published in: Education, Technology, Business

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
247
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. SMi present the 7th annual conference... 11th - 12th NOV 2014Marriott Regents Park Hotel, London, UK Advances in Cell Based Assays @SMIpharm www.cellbasedassay.co.uk Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 CONFERENCE CHAIRS: • Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK • Dr Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D KEY SPEAKERS INCLUDE: • Dr Lesley Jenkinson, Scientist 1, Medimmune • Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB • Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh • Davide Danovi, Director, HipSci Cell Phenotyping, Guy's Hospital • Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma, Denmark • Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono • Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis • Anker Jon Hansen, Principal Scientist, Novo Nordisk • Daniel Nolan, Director of Research, Angiocrine Bioscience • Jonathan Rock, Senior Sales Specialist-Emerging Technologies, Sigma Aldrich Explore the latest developments to extend your market dominance REGISTER BY 18TH JULY AND RECEIVE A £300 DISCOUNT REGISTER BY 30TH SEPTEMBER AND RECEIVE A £100 DISCOUNT PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS Thursday 13th November 2014, Marriott Regents Park Hotel, London, UK A: Unleashing the power of advanced cell-based assays to fuel open innovation Workshop Leader: Niclas Nilsson, Open Innovation Manager, Early Pipeline and Innovation Centre, LEO Pharma, Denmark 8.30am – 12.30pm B: A critical evaluation of cell-based assays in pre-clinical drug discovery Workshop Leader: Sheraz Gul, Vice President and Head of Biology, European ScreeningPort GmbH 1.30pm – 5.30pm BENEFITS OF ATTENDING: • New for 2014 - cell based assays and regulatory guidelines – what you need to know! • New for 2014 - Peep into the future with a look at next generation cell based assays • Discover new and novel approaches for the application of 3D cell cultures • Hear the latest on stem cell developments including gene editing technologies • Hear from over 8 pharma plus academics who will share their expert knowledge in cell based assays! Sponsored by
  • 2. Register online at: www.cellbasedassay.co.uk • Alternatively fax y Advances in Cell Based Assays Conference Day One | Tuesday 11th November 2014 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK REGULATORY UPDATE AND DRUG DEVELOPMENTS 9.10 Cell based assays in biologics drug discovery •Cell based assays are the assays of choice for identifying functionally active therapeutics with the right epitope and mechanism of action •The use of cell based assays for high throughput testing of un-purified biologics samples is challenging due to sample tolerance and assay sensitivity •Recent advances in high throughput sample expression techniques have opened up new possibilities for primary HTS within the biologics industry •The application of cell based assays in biologics discovery, and the use of new higher throughput sample expression techniques for cell-based primary HTS will be described Lesley Jenkinson, Scientist 1, Antibody Discovery and Protein Engineering, Medimmune 9.50 Challenges of bioassay methods development and validation with reference to cell based assays & regulatory guidelines in drug development •Cell based assays are highly variable and pose numerous challenges in drug development and technology transfer from analytical laboratories to quality control •Discuss strategies to development and validation •Review current regulatory thinking (EMA and US-FDA) Dr Niranjan Kumar, Ph.D, EMBA, President, ABS Inc. USA 10.30 Morning Coffee 10.50 Using immunological human in vitro assays and their corresponding in vivo model systems to determine target specific mode of action of small and large molecules •Specific immunological human and mouse in vitro assay and their corresponding in vivo models will be discussed •How can these models be used to determine functionality and potency of different molecules and how translatable are these findings into the clinic Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB 11.30 The many assay approaches for assessing mitochondrial toxicity, and their strategic use in drug development •Indirect, direct and mechanistic assays •Integrated approaches •When, what and how to assess •Case studies Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis 12.10 Networking Lunch 1.10 Use of the single cell gel electrophoresis (comet) assay in drug development Professor John A Hartley, Professor of Cancer Studies, Co-Lead, UCL Experimental Cancer Medicine Centre, UCL and Founder Scientist and Director of Pre-Clinical Development, Spirogen Ltd PHENOTYPIC SCREENING USING CELL BASED ASSAYS 1.50 Aligning Drug Discovery Critical Paths to Clinical Translation with Human Disease Relevant Cell based assays •Current focus on translationally-aligned drug discovery approaches •Potential to accelerate the uptake of primary cell screening systems •Increased usage of phenotypic assays and primary screening activities for hit identification Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK 2.30 Next Generation Target Identification and Screening Technologies. •An overview of High Content Screening technologies and their applications including:- - Genome Editing Tools (ZFN, CRISPR) - Custom Engineered cell lines and disease models - Protein-Protein interaction detection (Duolink) - RNAi and miRNA technologies. Jonathan Rock, Senior Sales Specialist-Emerging Technologies, Sigma Aldrich 3.10 Afternoon Tea 3.40 Development of phenotypic and disease-relevant in vitro assays for open innovation •Changing business need for classic in vitro assays •Gearing up early in vitro drug research for global innovation •Practical hurdles when developing advanced cell-based assays for open innovation Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma, Denmark LABEL FREE 4.20 Reviewing the value of electrical impedance sensing for label- free detection of cellular pharmacology •Analysing how this method is ideal for measuring cell adhesion and growth •Understanding how cell death can be measured on-line - and how cell activation can be monitored •Discussing endothelial/epithelial barrier function Anker Jon Hansen, Scientific Director,Cellular Pharmacology, Novo Nordisk 5.00 How easy or not is it to use adult stem cells in therapeutic applications, in vitro and in vivo paradigm? •Discussing how these "adult stem cells" have been developed using virus particles •For differentiating into specific tissues/organs what are the potential road blocks and or barriers with reference to regulatory, safety issues? •Analysing the challenges and safety concerns of future stem cell and cell based assay technologies and how to overcome them Dr. Niranjan Kumar, Ph.D, EMBA, President, ABS Inc. USA 5.40 Chairman's Closing Remarks and Close of Day One SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk PANEL DISCUSSION Sponsored by Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. www.sigma-aldrich.com
  • 3. Supported by your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Day Two | Wednesday 12th November 2014 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Dr Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D STEM CELLS 9.10 Gene editing technologies in the context of cell based assays •Exploiting gene-editing in human cell lines to provide novel, isogenic assays •What technologies are available •How are these impacting the industry Ashley Barnes, Group Leader, Biological Sciences, GSK 9.50 High content analysis using stem cells for disease modelling and drug discovery •Current challenges in the use of stem cells in phenotype screening •Defining boundaries between health and disease at a single cell level •The human induced pluripotent stem cell initiative cell phenotyping strategy Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London 10.30 Morning Coffee 10.50 VeraVec endothelial cells recreate the vascular stem cell in vitro for stem cell expansion and drug discovery •The vascular stem cell niche is capable of expanding stem cells in vitro while maintaining potency and engraftability •The VeraVec platform has applicability for various stem cells; UCB, iPSC, hESC, neural, malignant, etc •VeraVec ECs are amenable to 3D and co-culture assays for screening purposes •Recent work has demonstrated the chemoresistant niche within cancer involves the vasculature, which is also modeled by VeraVecs Dr. Daniel Nolan, Director of Research, Angiocrine Bioscience APPLICATION OF 3D CULTURES 11.30 Introducing 3D cell culture in oncology research •The first lab-grown epidermis with a functional barrier is an efficient and cost-effective alternative in vitro model for testing drugs and cosmetics •Use of human embryonic stem cells (hSEC) or induced pluripotent stem cells (iPSC)-derived keratinocytes allow an unlimited number of genetically identical HEE units •Easy to be scaled up and adapted to cGMP requirements •Model to study how the skin barrier develops normally, how the barrier is impaired in different diseases and how we can stimulate its repair and recovery Dr Dusko Ilic MD PhD, Reader in Stem Cell Science, Division of Women's Health, King's College London 12.10 Networking Lunch 1.10 3D cell culture developments in technology to improve in vitro analyses •Developments in vitro cell based assay application of 3d culture with enhanced cell structure and function •Understanding why 3D cell culture technologies are essential for pharmaceutical research •Reviewing the newest developments in the key areas of 3D cell culture technologies - advanced 3D cell culture models for efficacy and safety studies - enabling technologies to create and analyze biological reactions - successful implementation in compound de-risking •Newest developments in the key areas of 3D cell culture technologies Dr, Magnus Ingelman-Sundberg, Professor, Section Head, Vice Chairman, Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet NEXT GENERATION CELL BASED ASSAYS 1.50 Next generation phenotypic screening •Evaluating how to implement a more holistic approach that incorporates phenotypic approach and molecular or target-based discovery modes •Reviewing companies that use phenotypic drug discovery, what are the findings? •Examining the challenges of phenotypic screening. •Future perspectives – 3D, 2D, tissues, where are we going? Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh 2.30 Afternoon Tea 2.50 Advancing drug discovery success through phenotypic profiling •Strategies for driving impact across the value chain •Practices and technological innovations in HCA, cell biology and data analytics as success factors to application •Case scenarios on the utilisation of a phenotypic compound profiling platform at AstraZeneca Dr Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D 3.30 Reviewing the steps to more physiological cell models •Discussing high content screening •Primary cells •Introducing 3D models Dr. Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono 4.10 Chairman’s Closing Remarks and Close of Day Two Official Media Partner Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email tarri@smi-online.co.uk
  • 4. HALF-DAY POST-CONFERENCE AM WORKSHOP Thursday 13th November, 2014 8.30am – 12.30pm Marriott Regents Park Hotel, London, UK A: Unleashing the power of advanced cell-based assays to fuel open innovation Workshop Leader: Niclas Nilsson, Open Innovation Manager, Early Pipeline and Innovation Centre, LEO Pharma A/S Overview of Workshop: The workshop will touch upon the combination of cell-based, phenotypic assay and open innovation - how internal in vitro assets can be used better to drive drug research innovation and create external collaboration opportunities. The focus of the workshop is how to develop and use advanced cell- based assays in open innovation platforms. Why you should attend: • Get introduced to the concept of open assay access to fuel open innovation • Understand critical hurdles and how to address them • Hear about what cell-based assays should be able to deliver as an open innovation asset • Discuss key parameters to attract partners to your asset, or how your asset could provide value for someone elsegeneric. Programme: 8.30 Registration and coffee 9.00 Opening remarks 9.10 Session 1. Overview of existing open innovation in drug research • What is Open Innovation • Pharma examples • Intentions – what we want to achieve and how to do it 9.50 Session 2. Open access to advanced-cell based assays • Examples of existing assays • What to consider when developing the assay platform • Disease-relevant phenotypic assays 10.30 Coffee break 11.00 Session 3. Overcoming practical issues during implementation • Potential legal issues • Material transfer agreement • Compounds management • Joining internal and external assay process flows • Data and results 11.40 Session 4. Spinning in the outcome – how to handle positive results and generate business value • Follow-up studies • Overcoming “not invented here” mentality • Fueling the pipeline 12.20 Closing remarks 12.30 End of workshop About the workshop host: Niclas Nilsson MSc PhD, has a 10 years’ experience in pharmaceutical in vitro assay development with focus on advanced cell- based assays, including phenotypic assay to forward drug research. Recently Niclas has focused on creating collaborative opportunities using cell-based assays as an open innovation platform to meet the growing need for boosting R&D innovation and external collaboration. About Leo Pharma: Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company which is fully foundation owned. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. LEO Pharma has its own sales forces in 61 countries and employs around 4,800 employees worldwide. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
  • 5. HALF-DAY POST-CONFERENCE PM WORKSHOP Thursday 13th November 2014 1.30pm - 6.00pm Marriott Regents Park Hotel, London, UK A critical evaluation of cell-based assays in pre-clinical drug discovery Workshop Leader: Sheraz Gul, Vice President and Head of Biology, EuropeanScreening Port GmbH Overview of Workshop: A typical small molecule drug discovery project will aim to identify chemical starting points that modify the functions of genes, cells, or biochemical pathways. In some but not all instances, these functions may be linked to disease processes, and an opportunity will exist to further develop the chemical starting points into novel therapeutic agents. We have witnessed a resurgence of cell-based assays in pre-clinical drug discovery and this workshop will critically evaluate both target-based biochemical assays and cell-based assays, with the ultimate aim of these to reduce compound attrition and the enable the successful translation of compound activities in vivo. Why you should attend: The workshop is designed for scientists at all levels from core facilities, contract research organisations within academic and industrial research organisations engaged in early stage drug discovery who have an interest in the development, validation and utilisation of cell-based assays for screening against small molecule libraries. It is anticipated that the workshop will extend the expertise of the participants. Programme: 1.30 Registration and coffee 2.00 Opening remarks 2.15 Session1:Drugdiscovery,chemicalbiologyandprobe discovery • A historical overview of drug discovery, chemical biology and probe discovery including case studies 3.00 Session 2: Target-based biochemical assays in pre- clinical drug discovery • An overview of target-based biochemical assays that are employed in pre-clinical drug discovery 3.45 Coffee break 4.15 Session 3: Cell-based assays in pre-clinical drug discovery • An overview of cell-based assays that are employed in pre-clinical drug discovery 5.00 Session 4: Integrating your research program, design of project critical paths which integrate in-vitro, in-silico and in-vivo elements • Construction of critical pathways for pre-clinical drug discovery projects, appreciate that a variety of tools are required to ensure project progression 5.45 Closing remarks 6.00 End of workshop About the workshop host: Sheraz Gul has been the Vice President and Head of BiologyatEuropeanScreeningPortGmbH,Hamburg, Germany since 2008 where he manages the assay development and screening of academic drug targets. Prior to this, he worked for GlaxoSmithKline for 7 years where he developed biochemical and cellular assays for High Throughput Screening as well as Hit characterization.HehasaPhDand5yearspost-doctoralresearch experience all from the University of London. He has co-authored numerouspapers,bookchaptersandtheEnzymeAssays:Essential Data Handbook. In addition, he has been appointed to the editorial boards of the European Pharmaceutical Review and International Drug Discovery, is the Scientific Editor of Drug Target Review, a scientific co-founder of Transcriptogen Ltd and is an advisor to a number of biotech companies. He is involved in various EU-FP7, IMI and COST Action projects where he leads various work-packages and is involved in translating basic research to drug discovery. In addition, he co-ordinates the 3 day practical workshops run at the European ScreeningPort GmbH in conjunction with the European Pharmaceutical Review and is the joint co-ordinator of the EMBL Master Course-Chemical Biology Screening. About The European ScreeningPort: The European ScreeningPort GmbH (ESP) is a Public Private Partnership which receives project-based funding from national governments, industry and academic institutions. ESP offers industry scale small molecule Hit-finding capability to academic organisations within Europe and collaborates closely with the pharmaceutical industry in multiple projects.Approximately50%oftheESPHitfindingprojectsinvolve cell-basedassayreadouts.TheESPprovidesscreeningservicesto multiple academic partners from across the globe.
  • 6. FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK ADVANCES IN CELL BASED ASSAYS CONFERENCE Conference: Tuesday 11th & Wednesday 12th November 2014, Marriott Hotel Regents Park, London, UK Workshops: Thursday 13th November 2014, London 4 WAYS TO REGISTER www.cellbasedassay.co.uk If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. Unique Reference Number Our Reference LVP-122 Terms and Conditions of Booking DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: Department/Division: Company/Organisation: Email: Company VAT Number: Address: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Mobile: Switchboard: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. ACCOUNTS DEPT Title: Forename: Surname: Email: Address (if different from above): Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 □ Book by 18th July to receive £300 off the conference price □ Book by 30th September to receive £100 off the conference price EARLY BIRD DISCOUNT Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-122 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 □ Cheque We can only accept Sterling cheques drawn on a UK bank. □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Cardholder’s Name: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): LIVE STREAMING/ON DEMAND/ DOCUMENTATION Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room. Price Total □ Live Streaming £999.00 + VAT (UK) £1198.80 □ On demand £599.00 + VAT (UK) £718.80 (available 24 hours after the event) □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations - paper copy £499.00 - £499.00 (or only £300 if ordered with the Document Portal) PAYMENT VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________________ CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference and 2 Workshops £2697.00 +VAT £3236.40 □ Conference and 1 Workshop £2098.00 +VAT £2517.60 □ Conference only £1499.00 +VAT £1798.80 □ 2 Workshops only £1198.00 +VAT £1437.60 □ 1 Workshop only £599.00 +VAT £718.80 PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80 The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.

×